Drug intelligence / Profile preview

VRB-102

Development stage: Unknown
Lead developer: Verdiva Bio
Modality: Peptides, Small Molecules
Administration: Subcutaneous

Overview

VRB-102 is an injectable, once-weekly dual amylin and calcitonin receptor agonist (DACRA) being developed by Verdiva Bio for the treatment of obesity and related cardiometabolic disorders. It is designed as a long-acting peptide that activates both amylin and calcitonin receptors to enhance satiety, reduce food intake, and promote weight loss, and is intended for use in combination with Verdiva’s oral GLP-1 agonist VRB-101 to achieve greater and more durable body-weight reduction than single-pathway incretin therapy.[1][3][7]

Targets

CALCR (Calcitonin receptor)AMY receptor (Calcitonin receptor (with ramps))

Beyond the preview

Go deeper on VRB-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on VRB-102.

Explore the full profile